Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alto Neuroscience (ANRO) Total Debt (2023 - 2026)

Alto Neuroscience has reported Total Debt over the past 4 years, most recently at $16.0 million for Q1 2026.

  • Quarterly results put Total Debt at $16.0 million for Q1 2026, down 19.65% from a year ago — trailing twelve months through Mar 2026 was $16.0 million (down 19.65% YoY), and the annual figure for FY2025 was $16.8 million, up 63.42%.
  • Total Debt reached $16.0 million in Q1 2026 per ANRO's latest filing, down from $16.8 million in the prior quarter.
  • Across five years, Total Debt topped out at $20.3 million in Q3 2025 and bottomed at $9.9 million in Q4 2023.
  • Median Total Debt over the past 4 years was $13.1 million (2024), compared with a mean of $14.3 million.
  • The largest annual shift saw Total Debt skyrocketed 100.22% in 2025 before it dropped 19.65% in 2026.
  • Over 4 years, Total Debt stood at $9.9 million in 2023, then rose by 3.99% to $10.3 million in 2024, then skyrocketed by 63.42% to $16.8 million in 2025, then fell by 4.39% to $16.0 million in 2026.
  • Business Quant data shows Total Debt for ANRO at $16.0 million in Q1 2026, $16.8 million in Q4 2025, and $20.3 million in Q3 2025.